Zurex Pharma is launching a phase III clinical trial of its lead compound after raising more than $6 million.

The Middleton company, whose anti-microbial products aim to reduce the risk of infections during surgery, has raised much of the $8 million it’s seeking in this series C round. The company’s looking to help reduce hospital-acquired infections, which are penalized under the Affordable Care Act.

See the SEC filing: